Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00569842 · ClinicalTrials.gov registry record
Investigation of the Cylex® ImmuKnow® Assay
A clinical trial, sponsored by Indiana University.
- Completed
- Registry status
- 45
- Enrollment target
NCT00569842: Completed study, sponsored by Indiana University.
NCT00569842 is a clinical trial that has completed, run by Indiana University. The registered enrollment target is 45 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00569842 has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- 45 participants
- Enrollment target
Study Summary
Currently, there is no accurate way of predicting the occurrence of Graft vs Host Disease (GvHD) or infection. The purpose of this study is to analyze blood with the ImmuKnow® Assay to see if doctors can detect which patients are at risk for GvHD and for getting an infection before they occur.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2007-11 |
| Est. Completion | 2012-12 |
What the finished NCT00569842 record still lists
NCT00569842 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 45 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00569842 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00569842 about?
NCT00569842 is a clinical study titled "Investigation of the Cylex® ImmuKnow® Assay". Currently, there is no accurate way of predicting the occurrence of Graft vs Host Disease (GvHD) or infection. The purpose of this study is to analyze blood with the ImmuKnow® Assay to see if doctors can detect which patients are at risk for GvHD and for getting an infection before they occur.
What is the current status of trial NCT00569842?
This trial is currently completed. The enrollment target is 45 participants. The study started on 2007-11. Estimated completion is 2012-12.
Who is sponsoring clinical trial NCT00569842?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia